orchard_logo.jpg
Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)
December 08, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, yesterday reported initial data from an ongoing proof-of-concept...
orchard_logo.jpg
Orchard Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D....
orchard_logo.jpg
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)
November 19, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
orchard_logo.jpg
Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event Tomorrow at 9:00 a.m. ET
November 12, 2020 16:01 ET | Orchard Therapeutics (Europe) Limited
First look at preclinical data in frontotemporal dementia with progranulin mutations (GRN-FTD) and new amyotrophic lateral sclerosis (ALS) program NOD2 mutation revealed as Crohn’s disease (CD)...
orchard_logo.jpg
Orchard Therapeutics to Present at Barclays Gene Editing & Gene Therapy Summit
November 09, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene...
orchard_logo.jpg
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting
November 05, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the presentation of new clinical data at the...
orchard_logo.jpg
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results
November 03, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
Libmeldy TM Receives Positive CHMP Opinion for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD); U.S. IND Application on Track for Year End 2020 Cash and Investments of More Than $200M...
orchard_logo.jpg
Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020
November 02, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New...
orchard_logo.jpg
Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine’s 2021 Board of Directors
October 22, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company’s chief executive officer, Bobby...
orchard_logo.jpg
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
October 16, 2020 06:00 ET | Orchard Therapeutics (Europe) Limited
First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants One-time treatment with Libmeldy...